Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

BACKGROUND: This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. METHODS: A total number of 135 firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Changhui, Nie, Wei, Guo, Jingdong, Xiong, Anning, Zhong, Hua, Chu, Tianqing, Zhong, Runbo, Xu, Jianlin, Lu, Jun, Zheng, Xiaoxuan, Zhang, Bo, Shen, Yinchen, Pan, Feng, Han, Baohui, Zhang, Xueyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114713/
https://www.ncbi.nlm.nih.gov/pubmed/33975616
http://dx.doi.org/10.1186/s12931-021-01741-9

Ejemplares similares

Ejemplares similares